# Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

> **NCT02315768** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 32 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** GA101
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02315768
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-26
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-04-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315768, "Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02315768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*